The interaction of SET and protein phosphatase 2A as target for cancer therapy.

Biochimica Et Biophysica Acta. Reviews on Cancer
E C DacolA P Lepique

Abstract

In cancer cells, tumor suppressor proteins loss-of-function are usually the result of genetic mutations. Protein Phosphatase 2A is a tumor suppressor that inactivates several signaling pathways through removal of phosphate residues important for other proteins stability and/or activation. Different from other tumor suppressors, PP2A is, in many cancer types, inactivated by endogenous inhibitors. In physiological conditions, these inhibitors are important to balance PP2A activity. However, in cancer cells, overexpression of these inhibitors can keep PP2A inactive, resulting in sustained activation of mitogenic signaling pathways and transcription factors, metabolic reprogramming, with the resulting cancer progression and the resistance to anti-cancer therapies. One of these endogenous inhibitors is the protein SET (SE Translocation). SET is a multifunctional protein, which high expression has been associated with several types of cancer, as well as other diseases such as Alzheimer's disease. Disruption of the interaction between SET and PP2A to rescue the activity of PP2A may represent a new therapeutic strategy and opportunity for cancer treatment. This review brings up-to-date advances on the interactions between SET and PP2A ...Continue Reading

References

May 10, 1996·The Journal of Biological Chemistry·M LiZ Damuni
Oct 17, 1998·Journal of the American Society of Nephrology : JASN·S G CarlsonB J Ballermann
Sep 29, 2000·Biochemical Pharmacology·S Zolnierowicz
Oct 25, 2003·Oncogene·Ann-Sofi Härmälä-BraskénJohn E Eriksson
Jan 6, 2005·Molecular and Cellular Biology·Matthew J GambleRobert P Fisher
Mar 25, 2005·Nature Methods·Sam A Johnson, Tony Hunter
Oct 22, 2005·The Journal of Biological Chemistry·Deanna G AdamsBrian E Wadzinski
Jan 25, 2007·The EMBO Journal·Jean Paul ten KloosterPeter L Hordijk
Feb 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jung-Hyuck AhnAngus C Nairn
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Shinsuke MutoMasami Horikoshi
Sep 9, 2008·The Journal of Biological Chemistry·Mengwei ZangZhijun Luo
Nov 26, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Archana MukhopadhyayBesim Ogretmen
Jan 1, 2009·Nature Reviews. Drug Discovery·Véronique Baud, Michael Karin
Jan 22, 2010·The New England Journal of Medicine·Jeffrey A CohenUNKNOWN TRANSFORMS Study Group
Feb 4, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Dale J ChristensenMichael P Vitek
Jun 28, 2011·Journal of Pharmacology & Pharmacotherapeutics·Sushil SharmaSparsh Gupta
Jun 8, 2012·Cancer Biology & Therapy·M Danielle BarefordPaul Dent
Dec 14, 2012·Nature Reviews. Cancer·Samy A F Morad, Myles C Cabot
Feb 5, 2013·Neurobiology of Aging·Guang YuXiaochuan Wang
Sep 4, 2013·The Journal of Clinical Investigation·Paolo NevianiDanilo Perrotti
Dec 7, 2013·Cellular and Molecular Life Sciences : CMLS·Kee-Beom KimSang-Beom Seo
Mar 29, 2014·Molecular Cancer Research : MCR·Amy S FarrellRosalie C Sears
Jun 14, 2014·Proceedings of the National Academy of Sciences of the United States of America·Mahnaz JanghorbanRosalie C Sears
Nov 13, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ion CristóbalJesús García-Foncillas
Aug 1, 2013·Biomolecular Concepts·Nunzia MigliaccioAnnalisa Lamberti
Aug 4, 2015·Cell Reports·Guang YangDavid E James
Sep 5, 2015·Epigenetics & Chromatin·Qian ZhangJennifer K Nyborg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Transcription

Impaired transcription is associated with the pathogenesis and progression of conditions such as Alzheimer's disease (AD). Here are the latest discoveries pertaining to transcription and AD.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Related Papers

The International Journal of Biochemistry & Cell Biology
Otto Kauko, Jukka Westermarck
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Paula González-AlonsoFederico Rojo
The International Journal of Biochemistry & Cell Biology
Caitlin M O'ConnorGoutham Narla
© 2021 Meta ULC. All rights reserved